List of Excipients in Branded Drug ALUNBRIG

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Takeda Pharmaceuticals America Inc	ALUNBRIG	brigatinib	63020-113	CELLULOSE, MICROCRYSTALLINE	2031-04-28
Takeda Pharmaceuticals America Inc	ALUNBRIG	brigatinib	63020-113	LACTOSE MONOHYDRATE	2031-04-28
Takeda Pharmaceuticals America Inc	ALUNBRIG	brigatinib	63020-113	MAGNESIUM STEARATE	2031-04-28

ALUNBRIG Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

ALUNBRIG (brigatinib) is a once-daily oral ALK tyrosine kinase inhibitor marketed by Takeda for ALK-positive metastatic non-small cell lung cancer. Its commercial formulation is a conventional immediate-release tablet available in 30 mg, 90 mg and 180 mg strengths. The main excipient opportunities are not new chemical entities, but differentiated generic formulations, lactose-reduced or lactose-free tablets, improved swallowing formats, manufacturing-cost reductions, and region-specific supply strategies.

Brigatinib has a relatively favorable formulation profile: high potency, low daily dose, oral administration, no clinically meaningful food restriction, and a three-strength dose architecture. These characteristics reduce the need for complex delivery technology but create opportunities for lifecycle products that improve tolerability, adherence, excipient compatibility, and access.

What is ALUNBRIG and how is it formulated?

ALUNBRIG contains brigatinib, an ALK and ROS1 tyrosine kinase inhibitor. FDA-approved dosing begins with 90 mg once daily for seven days, followed by 180 mg once daily if tolerated. Patients who require dose reductions may use 60 mg, 90 mg or 120 mg daily regimens under the prescribing information, although the marketed tablet strengths are 30 mg, 90 mg and 180 mg.[1]

Attribute	ALUNBRIG profile
Active ingredient	Brigatinib
Therapeutic class	ALK tyrosine kinase inhibitor
Primary indication	ALK-positive metastatic NSCLC
Administration	Oral, once daily
Marketed strengths	30 mg, 90 mg, 180 mg
Commercial dosage form	Immediate-release film-coated tablet
FDA first approval	April 28, 2017
FDA first-line approval	May 22, 2020
Food administration	With or without food
Key dose-escalation feature	90 mg daily for 7 days, then 180 mg daily
Originator	Takeda Pharmaceuticals

The FDA-approved product uses standard tablet excipients, including lactose monohydrate and common tablet-binding, disintegrating, lubricating and coating materials. Exact excipient composition should be assessed against the current US prescribing information and applicable foreign product labels because formulation details can vary by market and strength.[1,2]

What excipients are used in ALUNBRIG tablets?

The formulation uses conventional immediate-release excipient classes:

• Lactose monohydrate as a diluent
• Microcrystalline cellulose as a filler and compression aid
• Sodium starch glycolate as a disintegrant
• Magnesium stearate as a lubricant
• Film-coating materials, including polymeric coating agents, plasticizers, pigments and anti-tacking components

This composition is consistent with a direct-compression or low-complexity wet-granulation strategy. The formulation does not depend on a lipid vehicle, enteric coating, modified-release matrix, or device-based delivery system.

The presence of lactose creates the clearest excipient-led differentiation opportunity. A generic manufacturer could develop a lactose-free formulation using mannitol, anhydrous dibasic calcium phosphate, pregelatinized starch, coprocessed excipients or alternative grades of microcrystalline cellulose, subject to bioequivalence and manufacturability requirements.

How does brigatinib’s pharmacokinetic profile affect excipient strategy?

Brigatinib is absorbed after oral administration and has a terminal half-life of approximately 25 hours, supporting once-daily dosing.[1] High-fat food increases exposure, but the FDA label permits administration with or without food because the effect is not considered clinically meaningful for routine use.[1]

That profile limits the commercial value of an elaborate food-independent formulation. A new product would need to demonstrate a material advantage over the existing product, such as:

• Reduced tablet size
• Better mechanical strength at the 180 mg dose
• Lower friability during distribution
• Improved disintegration under variable gastrointestinal conditions
• Reduced exposure variability
• Better performance after dose splitting or tablet manipulation
• Improved stability in hot and humid markets

The most attractive development path is a robust immediate-release tablet rather than an extended-release or lipid-based system. A modified-release formulation could reduce peak-related adverse effects in theory, but it would require new clinical and regulatory evidence and could disrupt a dosing regimen that is already once daily.

What formulation patents protect ALUNBRIG and where are the opportunities?

The core commercial protection for ALUNBRIG is likely to be concentrated in patents covering brigatinib composition of matter, therapeutic use, pharmaceutical compositions and manufacturing processes. Excipient selection alone generally provides weaker protection than a composition-of-matter patent or a clinically supported method-of-use patent.

Formulation patent opportunities

A differentiated formulation may support patent claims around:

• Specific excipient ratios
• Particle-size distributions
• Solid-state forms
• Amorphous or crystalline brigatinib dispersions
• Dissolution profiles
• Low-dose tablet uniformity
• Moisture-protective coatings
• Packaging systems that improve stability
• Lactose-free or sugar-free compositions
• Pediatric or geriatric dosage forms

The commercial strength of such claims depends on whether the formulation produces an unexpected technical effect. A simple substitution of lactose with mannitol may be commercially useful but may face weak patentability if the substitution is routine and does not materially improve performance.

Manufacturing and intellectual-property barriers

Manufacturing barriers are more likely to involve:

• Control of brigatinib particle size
• Blend uniformity at the 30 mg strength
• Content uniformity across multiple strengths
• Lubrication sensitivity
• Tablet hardness and disintegration balance
• Film-coating uniformity
• Control of degradation products
• Scale-up behavior during compression

The 30 mg tablet may present greater content-uniformity risk than the 180 mg tablet because the active represents a smaller proportion of the blend. A manufacturer that can use a common blend across all strengths may reduce validation and supply-chain costs, but the approach must maintain dose proportionality and dissolution performance.

When does ALUNBRIG lose exclusivity and what generic entry risks exist?

The FDA approved ALUNBRIG in 2017 under the accelerated approval pathway for previously treated ALK-positive metastatic NSCLC. FDA converted the indication to regular approval in 2020 after confirmatory evidence supported first-line treatment.[1,3]

Regulatory exclusivity

The key FDA milestones are:

Event	Date
Initial accelerated approval	April 28, 2017
Expanded first-line indication	May 22, 2020
Confirmatory regular approval	2020

Regulatory exclusivity and patent expiry are separate issues. The 2017 approval date does not by itself establish the date of generic launch. Generic entry depends on listed patents, pediatric exclusivity, patent-term adjustment, Paragraph IV litigation, settlements and any applicable market exclusivity.

Paragraph IV challenges

A generic applicant seeking early entry may file an Abbreviated New Drug Application with a Paragraph IV certification against relevant Orange Book patents. The likely challenge targets would include:

• Brigatinib composition patents
• Pharmaceutical-composition patents
• Method-of-use patents for ALK-positive NSCLC
• Patents covering dosage regimens or treatment sequencing

A formulation-only strategy may avoid certain composition claims but still face method-of-use exposure if the ANDA label includes the patented indication. The applicant can attempt a section viii carve-out for protected uses, but the commercial value of the remaining label depends on whether the non-carved-out indication is economically viable.

Because ALUNBRIG is a small-molecule product, biosimilar risk is not applicable. The competitive threat comes from conventional generics, authorized-generic strategies and competing ALK inhibitors.

Which companies compete with ALUNBRIG?

ALUNBRIG competes primarily in the ALK-positive NSCLC market, where physicians select among several targeted therapies.

Product	Active ingredient	Company	Formulation relevance
ALUNBRIG	Brigatinib	Takeda	Immediate-release film-coated tablets
Alecensa	Alectinib	Roche	Oral capsules/tablets depending market
Lorbrena	Lorlatinib	Pfizer	Oral tablets
XALKORI	Crizotinib	Pfizer	Oral capsules/tablets
Zykadia	Ceritinib	Novartis	Oral capsules/tablets
Ensartinib	Ensartinib	Xcovery/partner markets	Regional market entry risk

Alectinib and lorlatinib are the most important commercial comparators in the first-line setting. A formulation improvement for ALUNBRIG would need to compete against the clinical and adherence characteristics of those products, not only against the originator tablet.

The competitive landscape creates opportunities for:

• Lower-cost generic brigatinib
• Regional authorized generics
• Combination-packaging strategies
• Adherence-support packaging
• Smaller tablets for patients with dysphagia
• Dose-reduction packs for early tolerability management
• Formulations designed for institutional or specialty-pharmacy distribution

What commercial opportunities exist for ALUNBRIG excipients?

1. Lactose-free brigatinib tablets

A lactose-free version is the most straightforward differentiation opportunity. Potential benefits include broader use among patients with lactose intolerance, simplified excipient declarations and improved positioning in markets where lactose avoidance is commercially important.

The opportunity is moderate rather than transformational. Lactose intolerance does not generally require avoidance of the small quantity of lactose used in a tablet, and the product label would need to support any specific patient benefit. The commercial value would therefore come mainly from portfolio differentiation and procurement preferences.

2. Smaller and easier-to-swallow tablets

The 180 mg dose may require a relatively substantial tablet mass. A high-load formulation using a more efficient filler, granulation process or particle-engineering approach could reduce tablet dimensions.

Potential excipient systems include:

• Coprocessed cellulose-based excipients
• Mannitol-based direct-compression systems
• Spray-dried lactose alternatives
• Low-moisture starch systems
• Silicified microcrystalline cellulose

A smaller tablet could improve adherence in older patients and those receiving multiple oral oncology medicines.

3. Dose-reduction packaging

ALUNBRIG has dose-modification requirements for pulmonary toxicity, hypertension, bradycardia, elevated creatine phosphokinase, lipase and other adverse events.[1] Packaging that supports 30 mg and 90 mg dose adjustments could reduce dispensing errors.

Commercial formats could include:

• Starter packs with 90 mg tablets for seven days and 180 mg tablets thereafter
• Dose-reduction packs combining 30 mg and 90 mg tablets
• Calendar blister packs
• Hospital and specialty-pharmacy titration kits

This is more likely to produce commercial differentiation through packaging and logistics than through a new excipient claim.

4. Pediatric and geriatric formulations

An oral suspension, dispersible tablet or multiparticulate formulation could expand use for patients unable to swallow conventional tablets. Such a product would face several technical challenges:

• Dose uniformity at low concentrations
• Chemical and physical stability in liquid media
• Taste masking
• Compatibility with enteral feeding tubes
• Device dosing accuracy
• Preservation and microbial control

The adult NSCLC market is the immediate commercial base, so a pediatric formulation would need a defined clinical or regulatory target. A geriatric-oriented small tablet or dispersible formulation may have a more practical opportunity.

5. Moisture-protective and low-cost supply strategies

A robust formulation with standard excipients can reduce cost, but packaging must preserve stability during transport and storage. Commercial opportunities include:

• High-barrier blister packaging
• Lower-cost bottle systems with desiccants
• Region-specific packaging configurations
• Reduced coating weight
• Excipient sourcing from multiple qualified suppliers
• Continuous manufacturing for high-volume generic production

For emerging markets, the lowest total delivered cost may matter more than excipient novelty. A formulation that tolerates high humidity and reduces packaging complexity could improve margins and reduce product loss.

How strong is the ALUNBRIG formulation estate?

The formulation estate is likely weaker than the underlying active-ingredient and therapeutic-use estate unless it contains claims tied to a specific solid form, dissolution profile, stability result or manufacturing process. Conventional excipient substitutions generally provide limited exclusivity because many alternative materials are known and interchangeable.

The strongest formulation strategies would combine:

1. A defined brigatinib solid state or particle property.
2. A narrow excipient ratio that solves a measurable manufacturing problem.
3. A dissolution or stability advantage.
4. A clinically relevant administration benefit.
5. Claims that are difficult to design around without losing performance.

For a generic entrant, the preferred strategy is usually to develop a non-infringing immediate-release tablet using alternative fillers and disintegrants, then validate bioequivalence against the reference product. For a branded lifecycle product, the investment case is stronger when the excipient change supports a new patient segment or materially improves dosing convenience.

What is the FDA and Orange Book status of ALUNBRIG?

ALUNBRIG is FDA-approved and listed as an oral tablet product for brigatinib. Its FDA regulatory history includes accelerated approval in 2017 and regular approval of the first-line indication in 2020.[1,3]

The Orange Book controls the current list of patents and regulatory exclusivities relevant to ANDA certification. Patent status can change through patent-term adjustment, pediatric exclusivity, litigation outcomes, settlements and listing corrections. A definitive generic-entry forecast must therefore use the live Orange Book record and current court docket information rather than the approval date alone.

What patent litigation and settlement issues affect ALUNBRIG?

Potential litigation would center on:

• Paragraph IV certifications
• Patent listing disputes
• Infringement claims involving the reference formulation
• Method-of-use claims for first-line ALK-positive NSCLC
• Settlement agreements that establish a licensed generic-entry date

Excipient-focused products may reduce exposure to formulation claims but do not necessarily avoid active-ingredient or method-of-use patents. A generic applicant must also evaluate whether its proposed label induces use of a patented treatment method.

Key Takeaways

• ALUNBRIG is a once-daily immediate-release brigatinib tablet marketed in 30 mg, 90 mg and 180 mg strengths.
• Its conventional excipient system creates limited value for complex drug-delivery technologies.
• The strongest near-term excipient opportunity is a lactose-free, smaller or more robust immediate-release tablet.
• Dose-reduction packaging is commercially relevant because ALUNBRIG has a structured dose-modification profile.
• Pediatric, geriatric and enteral-delivery formulations offer higher differentiation but require additional development and regulatory evidence.
• Generic developers can likely design around conventional formulation claims through alternative fillers, disintegrants and coating systems.
• Biosimilar risk does not apply because brigatinib is a small molecule.
• Generic-entry timing depends on current Orange Book listings, Paragraph IV challenges, patent litigation and settlements.
• Manufacturing value is likely to come from content uniformity, moisture stability, tablet-size reduction and supply-chain resilience rather than novel excipient chemistry.

FAQs

Can ALUNBRIG be reformulated as an extended-release tablet?

Yes, but the commercial rationale is limited because ALUNBRIG is already dosed once daily. An extended-release product would need to demonstrate improved tolerability, reduced exposure variability or another clinically meaningful benefit.

Is a lactose-free brigatinib formulation commercially attractive?

It can support differentiation in generic and international markets. The opportunity is strongest when combined with smaller tablet size, improved stability or dose-reduction packaging.

Can brigatinib be developed as an oral suspension?

Technically, yes. The main challenges are dose uniformity, taste masking, chemical stability, microbial control and compatibility with administration devices or feeding tubes.

Does ALUNBRIG have biosimilar competition?

No. Brigatinib is a chemically synthesized small molecule regulated through the ANDA pathway rather than the biosimilar pathway.

Which excipient change is most likely to reduce manufacturing cost?

Replacing or optimizing high-cost fillers, simplifying granulation, reducing coating weight and qualifying multiple suppliers for lactose, microcrystalline cellulose, disintegrants and lubricants are the most practical cost-reduction routes.

References

1. U.S. Food and Drug Administration. (2024). ALUNBRIG (brigatinib) prescribing information. Takeda Pharmaceuticals U.S.A., Inc.

2. European Medicines Agency. (2024). Alunbrig: EPAR product information. European Medicines Agency.

3. U.S. Food and Drug Administration. (2020). FDA approves brigatinib for metastatic ALK-positive non-small cell lung cancer. FDA Oncology Center of Excellence.